Current Issues of Pharmacy and Medical Sciences

Involvement of biofilm-like intracellular bacterial communities of uropathogenic Escherichia coli in pathogenesis of urinary ...

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 3, Pages 321-325


Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, Poland 

DOI: 10.12923/j.2084-980X/26.3/a.18



This paper presents a precisely defined question about the role of the biofilm-like intracellular bacterial communities in pathogenesis of the urinary tract infections. According to the recent literature, uropathogenic Escherichia coli is one of the leading etiologic agents of the urinary tract infections. Although E. coli is regarded as an extracellular pathogen, some experiments have revealed a multi-step infection cycle, which involves adhesion, invasion, proliferation within invaded urothelial cell in the form of biofilm-like intracellular bacterial communities and dispersal, leading to infection of next neighbouring cells. Therefore, the prevention and treatment of the urinary tract infections must include intracellular stage of infection.

Files to download


urinary tract infections, uropathogenic E. coli, intracellular bacterial communities


  1. Andersen T.E. et al.: Escherichia coli uropathogenesis in vitro: invasion, cellular escape and secondary infection analyzed in a human bladder cell infection model. Infect. Immun., 80, 5, 2012.
  2. Anderson G.G. et al.: Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis. Infect. Immun., 78, 3, 2010.
  3. Ballester F.S. et al.: Cysticlean® a highly pac standardized content in the prevention of recurrent urinary tract infections: an observational, prospective cohort study. BMC Urol., 13, 1, 2013.
  4. Berry R.E., Klumpp D.J., Schaeffer A.J.: Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli. Infect. Immun., 77, 7, 2009.
  5. Bishop B.L. et al.: Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat. Med., 13, 5, 2007.
  6. Ejrnaes K.: Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Dan. Med. Bull., 58, 4, 2011.
  7. McGregor J.C. et al.: Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients. BMC Fam. Pract., 14, 25, 2013.
  8. Neuner E.A. et al.: Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob. Agents Chemother., 56, 11, 2012.
  9. Ofek I., Hasty D.L., Sharon N.: Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol. Med. Microbiol., 38, 3, 2003.
  10. Pignanelli S. et al.: In vitro antimicrobial activity of several antimicrobial agents against Escherichia coli isolated from community-acquired uncomplicated urinary tract infections. Eur. Rev. Med. Pharmacol. Sci., 17, 2, 2013.
  11. Schito G.C.: Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int. J. Antimicrob. Agents,  22, 2, 2003.
  12. Totsika M. et al.: A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug resistant uropathogenic Escherichia coli ST131. J. Infect. Dis., 2013 (in press).
  13. Ulett G.C. et al.: Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection. Curr. Opin. Microbiol., 16, 1, 2013.
  14. Wiles T.J., Kulesus R.R., Mulvey M.A.: Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp. Mol. Pathol., 85, 1, 2008.
  15. Zhou G. et al.: Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J. Cell Sci. 114, 22, 2001.
prev next



April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30